entertainment -WSS

entertainment

author：knowledge 2025-09-30 22:28:46 - browse：4144

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

focus

hotspot

WSS

White House drug czar issues call for 'recovery

After decades in use, heart stents finally beat placebo

White House drug czar issues call for 'recovery

Venture capitalist Bob Kocher on the state of digital health

NVIDIA and Google execs on the future of AI and drug discovery

Wearables generate powerful data but its not useful to doctors, yet

entertainment

entertainment

leisure time

Hollywood unions extend contract negotiations for actors

Study suggests Covid rebound is far more common with Paxlovid than without

Novavax promises a turnaround & Lilly roils the obesity market

Publishing genetic code of viruses could cause disaster

Duchenne breakthrough therapy leaves behind pioneering families

Helping hospitals and community health centers plan for resilience

Alkermes shareholders re

NVIDIA and Google execs on the future of AI and drug discovery

Activists slam private health insurers over coverage restrictions

Addiction experts warn against a second 'war on drugs'

knowledge

Healthy food access boosts outcomes in two studies

Study suggests Covid rebound is far more common with Paxlovid than without

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Healthy food access boosts outcomes in two studies

Today's health inequities arise from racist U.S. history, say experts

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

hotspot

focus

hotspot

knowledge